← ANALYST RATINGS · TIPRANKS
Akebia Therapeutics (AKBA): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy1 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $3.90, the highest $6.00, the lowest $1.00. The average is +482.1% from the last price of $0.67.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.80 → $0.73−8.8% | Hold | +8.5% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.77 → $0.71−8.8% | Hold | +5.4% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.74 → $0.68−8.9% | Hold | +1.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.80 → $0.73−8.9% | Hold | +9.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.73 → $0.67−8.8% | Hold | 0.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.80 → $0.73−8.9% | Hold | +9.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $4.00 | Buy | +497.0% | Reiterated | 14.09.26on TipRanks Sep 15 06:25 | +1.6%next day −5.7% · 5 days −4.4% | ↗ |
| Ed Arce★★★★★★★★★★#345 · hits 49% · avg +22.8% | Westpark Capital | $4.50 | Buy | +571.6% | Initiated | 08.09.26on TipRanks 08:30 | +6.3%next day −7.0% · 5 days −11.2% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $4.00 | Buy | +497.0% | Reiterated | 17.08.26on TipRanks 07:38 | −0.9%next day −0.4% · 5 days +5.8% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $1.00 | Hold | +49.3% | Downgrade | 07.08.26on TipRanks 06:25 | −5.3%next day −7.1% · 5 days −4.5% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $6.00 | Buy | +795.5% | Reiterated | 06.08.26on TipRanks 06:30 | −25.9%next day −5.3% · 5 days −10.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Akebia Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.90 at a price of $0.92 (+323.9%); now: $3.90 at $0.67 (+482.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 2 | 4 | 6 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.04 (from $-0.06 to $-0.02). Last quarter: $-0.03.
Sales
Next quarter’s sales estimate — $47M (from $43M to $51M). Last quarter: $49M.
Best top-analyst consensus in the sector · Healthcare
About Akebia Therapeutics
- CEO: John Butler
- Employees: 194
- 180 Third Avenue, Waltham, MA, 02451, US
- www.akebia.com
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Data from the stock’s TipRanks forecast page, read 134 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗